Day: July 22, 2025

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) — Gray Media, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) announced today that it intends to offer up to $700 million aggregate principal amount of senior secured first lien notes due 2033, subject to market conditions. The offering will be exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”). Gray intends to use the net proceeds of the offering, together with borrowings under Gray’s revolving credit facility, to (i) repay a portion of Gray’s term loan D due December 1, 2028 and (ii) repay a portion of Gray’s term loan F due June 4, 2029. The notes will be guaranteed, jointly and severally, on a senior secured first lien basis, by each existing and future restricted subsidiary of Gray that guarantees Gray’s existing senior credit facility. The...

TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) — Full Alliance Group, Inc. (OTC: FAGI) (“the Company”), today announced that its majority-owned subsidiary, Qubitera Holdings, Inc., has officially launched www.yahbee.com, an informational website introducing the Company’s next-generation affiliate wallet and financial ecosystem, YAHBEE. YAHBEE.COM is now live and provides early supporters, affiliates, and fintech enthusiasts the opportunity to explore the platform’s vision and sign up for priority updates as development continues. The YAHBEE wallet is currently in pre-launch phase and has not yet been released for public use or investment. “Our goal with YAHBEE is to reward everyday users — not just developers or whales — for growing a truly decentralized payment system,” said William “Billy” Heneghan Chairman of Full Alliance Group....

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) — Interparfums, Inc. (NASDAQ GS: IPAR) today announced that its subsidiary, Interparfums SA, has signed an exclusive fragrance license agreement with Longchamp, a Parisian Maison founded in 1948, through December 31, 2036. Interparfums SA will be responsible for the creation, development, production and distribution of fragrance lines in Longchamp-brand points of sale and selective distribution channels such as department stores, perfumeries and duty-free shops. The first launch is expected in 2027. Jean Cassegrain, Chairman & Chief Executive Officer of Longchamp, commented, “I look forward to working with Philippe Benacin and his teams to write this new chapter in the history of our Maison. We will cooperate in a spirit of enthusiasm to forge a new expression of our brand values: authenticity,...

SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Association International Conference 2025 (“AAIC 2025”) to be held in Toronto, Canada and online from July 27-31, 2025. Presentation details are as follows:Poster Title: Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer’s Disease Confirmed by Corresponding Phase I Biomarker...

The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2025 financial results after the market close on Wednesday, August 6, 2025. Catalyst’s management team will host a conference call and webcast on Thursday, August 7, 2025, at 8:30 AM ET to discuss the Company’s financial results and provide a business update. Conference Call & Webcast DetailsDate: August 7, 2025Time: 8:30 AM ETUS/Canada...

SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School...

American Rebel Holdings, IncMatt Hagan Win NHRA SeattleHagan, the four-time NHRA World Champion, recorded a string of strong runs in the NHRA Northwest Nationals to post his first 2025 NHRA Funny Car win Nashville, TN, July 22, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), is proud to congratulate Matt Hagen on his victory at the Muckleshoot Casino Resort NHRA Northwest Nationals. This victory marked Hagan’s first 2025 NHRA Funny Car win for the 4-time World Champion. Matt Hagan Powers to First Win of 2025 NHRA Season in Seattle, Vaults to Third in...

Philadelphia, PA, July 22, 2025 (GLOBE NEWSWIRE) —DriveItAway Holdings Inc. partners with Free2move, the global mobility brand of Stellantis. Launch of “Free2move Powered by DriveItAway”, enabling franchise dealers to offer flexible lease-to-own programs with no credit checks, no down payments, and no long-term commitments. Dealers become true mobility centers, offering on-demand vehicle access by the minute, day, week, or month through a seamless co-branded app. Program helps dealers capture new customers, boost service revenue, and compete directly with rental and subscription companies in the growing flexible-use market.In a bold move set to reshape the automotive landscape, DriveItAway Holdings, Inc. (OTC Marketplace: DWAY) (“DriveItAway” and “Company”) has joined forces with Free2move, the global mobility brand of Stellantis...

Ningbo, China, July 22, 2025 (GLOBE NEWSWIRE) — Skycorp Solar Group Limited (the “Company”) (NASDAQ: PN), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, today announced the adoption of cryptocurrency as an accepted method of payment for international transactions, effective August 1, 2025. The Company will support leading digital assets, including Bitcoin (BTC), Ethereum (ETH), and major stablecoins such as USDC and USDT. The Company also plans to allocate partial cash reserves and renewable energy project investment returns to strategic Ethereum (ETH) acquisitions as part of its long-term digital asset treasury management program. “By integrating green energy, AI and ETH-based blockchain solutions, the Company is innovating for a sustainable future,” said Weiqi Huang,...

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and...